{"id":"vinorelbine","rwe":[{"pmid":"41888166","year":"2025","title":"Symptomatic and pathological features in chemical phlebitis rat model by injection vinorelbine via dorsal pedal vein.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"},{"pmid":"41877717","year":"2026","title":"Vinorelbine enhances the efficacy of oncolytic vaccinia virus in a preclinical model of ovarian high-grade serous carcinoma.","finding":"","journal":"Molecular therapy. Oncology","studyType":"Clinical Study"},{"pmid":"41858972","year":"2025","title":"Locoregional recurrence of triple-negative breast cancer with low tumor-infiltrating lymphocytes: a case report.","finding":"","journal":"The Pan African medical journal","studyType":"Clinical Study"},{"pmid":"41855500","year":"2026","title":"Real-World Evidence for Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin in Classical Hodgkin Lymphoma.","finding":"","journal":"Blood advances","studyType":"Clinical Study"},{"pmid":"41851421","year":"2026","title":"Surface-engineered dual drug-loaded tumor-targeted liposomal nanoparticles to overcome the therapeutic resistance in glioblastoma multiforme.","finding":"","journal":"Communications medicine","studyType":"Clinical Study"}],"_fda":{"id":"dfa03517-f452-450c-8eb6-d946c0350248","set_id":"10a70995-e04d-4044-b1dc-c9aa27460397","openfda":{"unii":["253GQW851Q"],"route":["INTRAVENOUS"],"rxcui":["1729418","1729422"],"spl_id":["dfa03517-f452-450c-8eb6-d946c0350248"],"brand_name":["Vinorelbine"],"spl_set_id":["10a70995-e04d-4044-b1dc-c9aa27460397"],"package_ndc":["25021-204-01","25021-204-05"],"product_ndc":["25021-204"],"generic_name":["VINORELBINE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["VINORELBINE TARTRATE"],"manufacturer_name":["Sagent Pharmaceuticals"],"application_number":["ANDA091106"],"is_original_packager":[true]},"version":"10","pregnancy":["8.1 Pregnancy Risk Summary Based on findings from animal studies and its mechanism of action [see Clinical Pharmacology ( 12.1 )] , vinorelbine can cause fetal harm when administered to a pregnant woman. Available human data are insufficient to inform the drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies in mice and rabbits, embryo and fetal toxicity were observed with administration of vinorelbine at doses approximately 0.33 and 0.18 times the human therapeutic dose, respectively (see Data ) . Advise pregnant women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2 to 4% and 15 to 20%, respectively. Data Animal Data In a mouse embryo-fetal development study, administration of a single dose of vinorelbine at a dose level of 9 mg/m 2 or greater (approximately 0.33 times the recommended human dose based on body surface area) was embryotoxic and fetotoxic. Vinorelbine was embryotoxic and fetotoxic to pregnant rabbits when administered every 6 days during the period of organogenesis at doses of 5.5 mg/m 2 (approximately 0.18 times the recommended human dose based on body surface area) or greater. At doses that did not cause maternal toxicity in either species, vinorelbine administration resulted in reduced fetal weight and delayed ossification."],"overdosage":["10 OVERDOSAGE There is no known antidote for overdoses of vinorelbine. Overdoses involving quantities up to 10 times the recommended dose (30 mg/m 2 ) have been reported. The adverse reactions described were consistent with those listed in the ADVERSE REACTIONS section, including paralytic ileus, stomatitis and esophagitis. Bone marrow aplasia, sepsis and paresis have also been reported. Fatalities have occurred following overdose of vinorelbine. If overdosage occurs, general supportive measures together with appropriate blood transfusions, growth factors and antibiotics should be instituted as deemed necessary by the physician."],"references":["15 REFERENCES OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html"],"description":["11 DESCRIPTION Vinorelbine Injection, USP contains vinorelbine, a semi-synthetic vinca alkaloid. The molecular formula for vinorelbine tartrate is C 45 H 54 N 4 O 8 •2C 4 H 6 O 6. It has a molecular weight of 1079.11. The structural formula is as follows: Vinorelbine tartrate is a white to light yellow amorphous powder. It is easily soluble in water, very soluble in methanol and practically insoluble in hexane. Vinorelbine Injection, USP is a sterile nonpyrogenic aqueous solution for intravenous use. Each milliliter of solution contains 10 mg vinorelbine (equivalent to 13.85 mg vinorelbine tartrate) in Water for Injection, USP. The pH of Vinorelbine Injection, USP is approximately 3.5. Structural Formula"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Vinorelbine Injection, USP is supplied as follows: Vinorelbine Injection, USP NDC (10 mg per mL) Package Factor 25021-204-01 10 mg per mL Single-Dose Vial 1 vial per carton 25021-204-05 50 mg per 5 mL Single-Dose Vial 1 vial per carton Vinorelbine Injection, USP is a clear, colorless to pale yellow aqueous solution. Storage Conditions Store refrigerated between 2° and 8°C (36° and 46°F). Do not freeze. Protect from light. Retain in carton until time of use. Discard unused portion. Unopened vials of Vinorelbine Injection, USP are stable at 25°C (77°F) for up to 72 hours. Store diluted solutions of Vinorelbine Injection, USP at 5° to 30°C (41° to 86°F) [see Dosage and Administration ( 2.3 )] . Vinorelbine Injection, USP is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1 Sterile, Nonpyrogenic, Preservative-free. The container closure is not made with natural rubber latex."],"boxed_warning":["WARNING: MYELOSUPPRESSION Severe myelosuppression resulting in serious infection, septic shock, hospitalization and death can occur [see Warnings and Precautions ( 5.1 )]. Decrease the dose or withhold vinorelbine in accord with recommended dose modifications [see Dosage and Administration ( 2.2 )]. WARNING: MYELOSUPPRESSION See full prescribing information for complete boxed warning. Severe myelosuppression resulting in serious infection, septic shock, and death can occur ( 5.1 ). Decrease the dose or withhold vinorelbine in accord with recommended dose modifications ( 2.2 )."],"geriatric_use":["8.5 Geriatric Use Of the 769 number of patients who received vinorelbine as a single agent and in combination with cisplatin in studies 1, 2 and 3, 247 patients were 65 years of age or older. No overall differences in safety, efficacy and pharmacokinetic parameters were observed between these patients and younger patients [see Clinical Pharmacology ( 12.3 )] ."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of vinorelbine in pediatric patients have not been established. Results from a single-arm study of vinorelbine administered at the dose of 33.75 mg/m 2 (for 35 patients) or at the dose of 30 mg/m 2 (for 11 patients) every week for 6 weeks followed by 2 weeks of rest were evaluated (courses of 8 weeks). Forty-six patients age 1 to 25 (median 11 years) with recurrent solid malignant tumors, including rhabdomyosarcoma or undifferentiated sarcoma (N=21 patients), neuroblastoma (N= 4 patients) and central nervous system (CNS) tumors (N=21 patients), were enrolled. The most significant grade 3 or 4 hematological adverse reactions were neutropenia (70%) and anemia (33%). The most significant grade 3 or 4 non-hematological adverse reactions were motor (15%) or cranial (13%) neuropathy, hypoxia (13%) and dyspnea (11%). Objective tumor response was observed in 2 out of 21 patients with rhabdomyosarcoma or undifferentiated sarcoma. No objective tumor response was observed in patients with CNS tumors (N=21) or neuroblastoma (N=4)."],"effective_time":"20240816","clinical_studies":["14 CLINICAL STUDIES 14.1 Combination Use with Cisplatin The safety and efficacy of vinorelbine in combination with cisplatin was evaluated in two randomized, multicenter trials. Cisplatin 100mg/m 2 Study 1 was a randomized, multicenter, open-label trial of vinorelbine plus cisplatin and cisplatin alone for the treatment of stage IV or stage IIIb NSCLC in patients with malignant pleural effusion or multiple lesions in more than one lobe of the ipsilateral lung who had not received prior chemotherapy. A total of 432 patients were randomized 1:1 to receive either vinorelbine 25 mg/m 2 on Day 1 then every week of each 28-day cycle plus cisplatin 100 mg/m 2 administered on Day 1 of each 28-day cycle (N=214) or single agent cisplatin 100 mg/m 2 on Day 1 of each 28-day cycle (N=218). Patient demographics and disease characteristics were similar between arms. Of the overall study population, the median age was 64 (range 33 to 84), 66% were male, 80% were White, 92% had stage IV disease and 8% stage IIIB, 53% had adenocarcinoma, 21% squamous cell, 14% large cell histology. The major efficacy outcome measure was overall survival. The efficacy results are presented in Table 7 and Figure 1 . Table 7. Efficacy Results (Study 1) Vinorelbine plus Cisplatin (N=214) Cisplatin (N=218) Overall Survival Median Survival in months (95% CI) 7.8 (6.9, 9.6) 6.2 (5.4, 7.7) Unstratified log-rank p-value 0.01 Overall Response rate (ORR) Evaluable patients ORR (95% CI) N=206 19% (14%, 25%) N=209 8% (5%, 13%) Chi-square test p-value <0.001 Figure 1: Overall Survival Vinorelbine / Cisplatin versus Single Agent Cisplatin Figure 1 Cisplatin 120mg/m 2 Study 2 was a randomized, 3-arm, open-label, multicenter trial of vinorelbine plus cisplatin, vindesine plus cisplatin and vinorelbine as a single agent for the treatment of patients with stage III or IV NSCLC who had not received prior chemotherapy. The study was conducted in Europe. A total of 612 patients were randomized 1:1:1 to receive vinorelbine 30 mg/m 2 every week of a 6-week cycle plus cisplatin 120 mg/m 2 on Day 1 and Day 29, then every 6 weeks thereafter (N=206); and vindesine 3 mg/m 2 for 6 weeks, then every other week thereafter plus cisplatin 120 mg/m 2 on Days 1 and Day 29, then every 6 weeks thereafter (N=200) or vinorelbine 30mg/m 2 every week of a 6-week cycle (N=206). The main efficacy outcome measure was to compare overall survival between vinorelbine plus cisplatin and vindesine plus cisplatin. The other efficacy outcome measure was to compare overall survival in the better of the two combination regimens to that of vinorelbine as a single agent. Patient demographics were in general similar between arms: the median age of the overall population was 60 years (range 30 to 75), 90% were male, 78% had WHO performance status of 0 or 1. Tumor characteristics were in general similar with the exception of histologic subtype of NSCLC. Adenocarcinoma was the histologic subtype in 32% of patients in the vinorelbine plus cisplatin arm, 40% of patients in vindesine plus cisplatin arm and 28% of patients on the vinorelbine arm. Ten percent of the patients had stage IIIA disease, 28% stage IIIB and 50% stage IV. Twelve percent of the patients had received prior surgery or radiotherapy. The efficacy results of Study 2 are presented in Table 8 . Table 8. Efficacy Results (Study 2) 1 n/a = not applicable Vinorelbine (N=206) Vinorelbine plus cisplatin (N=206) Vindesine plus cisplatin (N=200) Median survival in months (99.5% CI) 7.2 (5.4, 9.1) 9.2 (7.4, 11.1) 7.4 (6.1, 9.1) Unstratified log-rank p-value n/a 1 0.087 0.05 n/a Overall Response (ORR) Evaluable Patients ORR (95% CI) N=205 14% (10%, 20%) N=203 28% (22%, 35%) N=198 19% (14%, 25%) Chi-square test p-value n/a 0.03 < 0.001 n/a 14.2 Single Agent The safety and efficacy of vinorelbine as a single agent was evaluated in one randomized multicenter trial. Study 3 was a randomized, open-label clinical trial of vinorelbine or fluorouracil (FU) plus leucovorin (LV) in patients with Stage IV NSCLC who had not received prior chemotherapy. A total of 211 patients were randomized 2:1 to receive vinorelbine 30 mg/m 2 weekly of an 8-week cycle (N=143) or FU 425 mg/m 2 bolus intravenously plus LV 20 mg/m 2 bolus intravenously daily for 5 days of a 4-weeks cycle (N=68). Patient demographics and disease characteristics were in general similar between arms. In the overall population, the median age was 61 years (range 32 to 83), 74% were male, 88% were White, 46% had adenocarcinoma histology. Fifty percent of the patients had Karnofsky performance status ≥ 90 in the vinorelbine arm compared to 38% in the FU/LV arm. The primary efficacy outcome of the study was overall survival. The median survival time was 30 weeks versus 22 weeks for patients receiving vinorelbine versus FU/LV, respectively (p=0.06). Partial objective responses were observed in 11.1% (95% CI=6.2%, 17.9%) and 3.5% (95% CI=0.4%, 11.9%) of patients who received vinorelbine and FU/LV, respectively."],"pharmacokinetics":["12.3 Pharmacokinetics The pharmacokinetics of vinorelbine were studied in 49 patients who received doses of 30 mg/m 2 administered as 15- to 20-minute constant-rate infusions. Vinorelbine concentrations in plasma decay in a triphasic manner. Distribution Steady-state volume of distribution (V SS ) values range from 25.4 to 40.1 L/kg. Vinorelbine demonstrated high binding to human platelets and lymphocytes. The free fraction was approximately 0.11 in human plasma over a concentration range of 234 to 1169 ng/mL. The binding to plasma constituents in cancer patients ranged from 79.6% to 91.2%. Vinorelbine binding was not altered in the presence of cisplatin, fluorouracil, or doxorubicin. Elimination The terminal phase half-life averages 27.7 to 43.6 hours and the mean plasma clearance ranges from 0.97 to 1.26 L/hr/kg. Metabolism Vinorelbine undergoes substantial hepatic elimination in humans, with large amounts recovered in feces. Two metabolites of vinorelbine have been identified in human blood, plasma and urine; vinorelbine N-oxide and deacetylvinorelbine. Deacetylvinorelbine has been demonstrated to be the primary metabolite of vinorelbine in humans and has been shown to possess antitumor activity similar to vinorelbine. Therapeutic doses of vinorelbine (30 mg/m 2 ) yield very small, if any, quantifiable levels of either metabolite in blood or urine. The metabolism of vinorelbine is mediated by hepatic CYP3A. Excretion After intravenous administration of radioactive vinorelbine, approximately 18% and 46% of administered radioactivity was recovered in urine and feces, respectively. In a different study, 10.9% ± 0.7% of a 30 mg/m 2 intravenous dose was excreted as parent drug in urine. Specific Populations Age has no effect on the pharmacokinetics (CL, V SS and t 1/2 ) of vinorelbine. Drug Interaction Studies The pharmacokinetics of vinorelbine are not influenced by the concurrent administration of cisplatin."],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Myelosuppression [see Warnings and Precautions ( 5.1 )] Hepatic Toxicity [see Warnings and Precautions ( 5.2 )] Severe Constipation and Bowel Obstruction [see Warnings and Precautions ( 5.3 )] Extravasation and Tissue Injury [see Warnings and Precautions ( 5.4 )] Neurologic Toxicity [see Warnings and Precautions ( 5.5 )] Pulmonary Toxicity and Respiratory Failure [see Warnings and Precautions ( 5.6 )] Most common adverse reactions (incidence ≥ 20%) are leukopenia, neutropenia, anemia, increased aspartate aminotransferase, nausea, vomiting, constipation, asthenia, injection site reaction and peripheral neuropathy ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals at 1-866-625-1618 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under varying designs and in different patient populations, the adverse reaction rates reported in one clinical trial may not be easily compared to those rates reported in another clinical trial and may not reflect the rates actually observed in clinical practice. Single Agent The data below reflect exposure to vinorelbine as a single agent administered at a dose of 30 mg/m 2 on a weekly basis to 365 patients enrolled in 3 controlled studies for metastatic NSCLC and advanced breast cancer. The population included 143 patients with previously untreated metastatic NSCLC (Study 3) who received a median of 8 doses of vinorelbine. The patients were aged 32 to 79 (median 61 years), 71% were male, 91% White, 48% had adenocarcinoma histology. The data also reflect exposure to vinorelbine in 222 patients with previously treated advanced breast cancer who received a median of 10 doses of vinorelbine. Vinorelbine is not indicated for the treatment of breast cancer. Selected adverse reactions reported in these studies are provided in Tables 1 and 2 . The most common adverse reactions (≥ 20%) of single agent vinorelbine were leukopenia, neutropenia, anemia, increased aspartate aminotransferase (AST), nausea, vomiting, constipation, asthenia, injection site reaction and peripheral neuropathy. The most common (≥ 5%) Grade 3 or 4 adverse reactions were neutropenia, leukopenia, anemia, increased total bilirubin, increased AST, injection site reaction and asthenia. Approximately 49% of patients with NSCLC who were treated with vinorelbine experienced at least one dose reduction due to an adverse reaction. Thirteen percent of patients discontinued vinorelbine due to adverse reactions. The most frequent adverse reactions leading to vinorelbine discontinuation were asthenia, dyspnea, nausea, constipation, anorexia, myasthenia and fever. Table 1: Hematologic Adverse Reactions Experienced in > 5% of Patients Receiving Vinorelbine *† : * Grade based on modified criteria from the National Cancer Institute version 1. † Patients with NSCLC had not received prior chemotherapy. The majority of the remaining patients had received prior chemotherapy. All Patients (N=365) (%) NSCLC (N=143) (%) Laboratory Hematologic Neutropenia < 2,000 cells/mm 3 90 80 < 500 cells/mm 3 36 29 Leukopenia < 4,000 cells/mm 3 92 81 < 1,000 cells/mm 3 15 12 Thrombocytopenia < 100,000 cells/mm 3 5 4 Anemia < 11 g/dl 83 77 < 8 g/dl 9 1 Hospitalizations due to neutropenic complications 9 8 Table 2: Non-hematologic Adverse Reactions Experienced in ≥ 5% of Patients Receiving Vinorelbine *† : * Grade based on modified criteria from the National Cancer Institute version 1. † Patients with NSCLC had not received prior chemotherapy. The majority of the remaining patients had received prior chemotherapy. ‡ Incidence of paresthesia plus hypesthesia. All Grades Grade 3-4 All Patients (%) NSCLC (%) All Patients (%) NSCLC (%) Laboratory Hepatic AST increased (N=346) 67 54 6 3 Bilirubin increased (N=351) 13 9 7 5 Clinical Nausea 44 34 2 1 Asthenia 36 27 7 5 Constipation 35 29 3 2 Injection site reaction 28 38 2 5 Injection site pain 16 13 2 1 Neuropathy peripheral ‡ 25 20 <2 1 Vomiting 20 15 2 1 Diarrhea 17 13 1 1 Alopecia 12 12 ≤1 1 Phlebitis 7 10 <1 1 Dyspnea 7 3 3 2 Myelosuppression: In clinical trials, Grade 3-4 neutropenia, anemia and thrombocytopenia occurred in 69%, 9% and 1%, respectively of patients receiving single agent vinorelbine. Neutropenia is the major dose-limiting toxicity. Neurotoxicity: Neurotoxicity was most commonly manifested as constipation, paresthesia, hyperesthesia and hyporeflexia. Grade 3 and 4 neuropathy was observed in 1% of the patients receiving single agent vinorelbine. Injection Site Reactions: Injection site reactions, including erythema, pain at injection site and vein discoloration, occurred in approximately one third of patients; 5% were severe. Phlebitis (chemical phlebitis) along the vein proximal to the site of injection was reported in 10% of patients. Cardiovascular Toxicity: Chest pain occurred in 5% of patients; myocardial infarction occurred in ˂0.1% of patients. Pulmonary Toxicity and Respiratory Failure: Dyspnea (shortness of breath) was reported in 3% of patients; it was severe in 2%. Interstitial pulmonary changes were documented. Other: Hemorrhagic cystitis and the syndrome of inappropriate ADH secretion were each reported in <1% of patients. In Combination with Cisplatin Table 3 presents the incidence of selected adverse reactions, occurring in ≥10% of vinorelbine treated patients reported in a randomized trial comparing the combination of vinorelbine 25 mg/m 2 administered every week of each 28-day cycle and cisplatin 100 mg/m 2 administered on day 1 of each 28-day cycle versus cisplatin alone at the same dose and schedule in patients with previously untreated NSCLC (Study 1). Patients randomized to vinorelbine plus cisplatin received a median of 3 cycles of treatment and those randomized to cisplatin alone received a median of 2 cycles of treatment. The incidence of Grade 3 and 4 neutropenia was significantly higher in the vinorelbine plus cisplatin arm (82%) compared to the cisplatin alone arm (5%). Thirty-five percent of the eligible patients in the combination arm required treatment discontinuation due to an adverse reaction compared to 19% in the cisplatin alone arm. Four patients in the vinorelbine plus cisplatin arm died of neutropenic sepsis. Seven additional deaths were reported in the combination arm: 2 from cardiac ischemia, 1 cerebrovascular accident, 1 multisystem failure due to an overdose of vinorelbine and 3 from febrile neutropenia. Table 3: Adverse Reactions Experienced by ≥ 10% of Patients on Vinorelbine plus Cisplatin versus Single Agent Cisplatin * * Graded according to the standard SWOG criteria version 1. † Categorical toxicity grade not specified Vinorelbine 25mg/m 2 plus Cisplatin 100 mg/m 2 (N=212) Cisplatin 100 mg/m 2 (N=210) All Grades (%) Grades 3 - 4 (%) All Grades (%) Grades 3-4 (%) Laboratory Hematologic Neutropenia 89 82 26 5 Anemia 89 24 72 <8 Leukopenia 88 58 31 <1 Thrombocytopenia 29 5 21 <2 Febrile neutropenia † N/A 11 N/A 0 Renal Blood creatinine increased 37 4 28 <5 Clinical Malaise/Fatigue/Lethargy 67 12 49 8 Vomiting 60 13 60 14 Nausea 58 14 57 12 Decreased appetite 46 0 37 0 Constipation 35 3 16 1 Alopecia 34 0 14 0 Weight decreased 34 1 21 <1 Fever without infection 20 2 4 0 Hearing impaired 18 4 18 <4 Injection site reaction 17 <1 1 0 Diarrhea 17 <3 11 <2 Paraesthesia 17 <1 10 <1 Taste alterations 17 0 15 0 Peripheral numbness 11 2 7 <1 Myalgia/Arthralgia 12 <1 3 <1 Phlebitis/Thrombosis/Embolism 10 3 <1 <1 Weakness 12 <3 7 2 Infection 11 <6 <1 <1 Respiratory tract infection 10 <5 3 3 Table 4 presents the incidence of selected adverse reactions, occurring in ≥10% of vinorelbine treated patients reported in a randomized trial of vinorelbine plus cisplatin, vindesine plus cisplatin and vinorelbine as a single agent in patients with stage III or IV NSCLC who had not received prior chemotherapy. A total of 604 patients received either vinorelbine 30 mg/m 2 every week plus cisplatin 120 mg/m 2 on Day 1 and Day 29, then every 6 weeks thereafter (N=207), vindesine 3 mg/m 2 for 6 weeks, then every other week thereafter plus cisplatin 120 mg/m 2 on Days 1 and Day 29, then every 6 weeks thereafter (N=193) or vinorelbine 30mg/m 2 every week (N=204). Patients randomized to vinorelbine plus cisplatin received a median of 15 weeks of treatment, vindesine plus cisplatin 12 weeks and vinorelbine received 13 weeks. Grade 3 and 4 neutropenia was significantly greater in the vinorelbine plus cisplatin arm (78%) compared to vindesine plus cisplatin (48%) and vinorelbine as a single agent (53%). Neurotoxicity, including peripheral neuropathy and constipation, was reported in 44% (Grade 3-4, 7%) of the patients receiving vinorelbine plus cisplatin, 58% (Grade 3-4, 17%) of the patients receiving vindesine and cisplatin and 44% (Grade 3-4, 8.5%) of the patients receiving vinorelbine as a single agent. Study discontinuation due to an adverse reaction was required in 27, 22 and 10% of the patients randomized to vinorelbine plus cisplatin, vindesine plus cisplatin and cisplatin alone arms, respectively. Table 4: Adverse Reactions Experienced by ≥ 10 % of Patients from a Comparative Trial of Vinorelbine Plus Cisplatin versus Vindesine Plus Cisplatin versus Single Agent Vinorelbine * * Grade based on criteria from the World Health Organization (WHO). † N=194 to 207; all patients receiving vinorelbine/cisplatin with laboratory and non-laboratory data. ‡ N=173 to 192; all patients receiving vindesine/cisplatin with laboratory and non-laboratory data. § N=165 to 201; all patients receiving vinorelbine with laboratory and non-laboratory data. ¦ Categorical toxicity grade not specified. ¶ Neurotoxicity includes peripheral neuropathy and constipation. Vinorelbine/Cisplatin † Vindesine/Cisplatin ‡ Vinorelbine § All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) Laboratory Hematologic Neutropenia 95 78 79 48 85 53 Leukopenia 94 57 82 27 83 32 Thrombocytopenia 15 4 10 3.5 3 0 Renal Blood creatinine increased ¦ 46 N/A 37 N/A 13 N/A Clinical Nausea/Vomiting 74 30 72 25 31 2 Alopecia 51 7.5 56 14 30 2 Neurotoxicity ¶ 44 7 58 17 44 8.5 Diarrhea 25 1.5 24 1 12 0.5 Injection site reaction 17 2.5 7 0 22 2 Ototoxicity 10 2 14 1 1 0 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of vinorelbine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Infections: pneumonia Immune system disorders: anaphylactic reaction, pruritus, urticaria, angioedema Nervous system disorders: loss of deep tendon reflexes, muscular weakness, gait disturbance, headache Ear and labyrinth disorders: vestibular disorder, hearing impaired Cardiac disorders: tachycardia Respiratory disorders: pulmonary edema Vascular disorders: pulmonary embolism, deep vein thrombosis, hypertension, hypotension, flushing, vasodilatation Gastrointestinal disorders: mucosal inflammation, dysphagia, pancreatitis Skin disorders: generalized cutaneous reactions (rash), palmar-plantar erythrodysesthesia syndrome Musculoskeletal and connective tissue disorders: jaw pain, myalgia, arthralgia General disorders and administration site conditions: injection site rash, urticaria, blistering, sloughing of skin Injury, poisoning and procedural complications: radiation recall phenomenon, dermatitis, esophagitis Laboratory abnormalities: electrolyte imbalance including hyponatremia Other: tumor pain, back pain, abdominal pain"],"contraindications":["4 CONTRAINDICATIONS None None"],"drug_interactions":["7 DRUG INTERACTIONS Inhibitors of CYP3A4: May cause earlier onset and/or increased severity of adverse reactions ( 7.1 ) 7.1 CYP3A Inhibitors Exercise caution in patients concurrently taking drugs known to inhibit CYP3A. Concurrent administration of vinorelbine with a CYP3A inhibitor may cause an earlier onset and/or an increased severity of adverse reactions."],"how_supplied_table":["
Vinorelbine Injection, USP
NDC(10 mg per mL)Package Factor
25021-204-01 10 mg per mL Single-Dose Vial 1 vial per carton
25021-204-05 50 mg per 5 mL Single-Dose Vial 1 vial per carton
"],"mechanism_of_action":["12.1 Mechanism of Action Vinorelbine is a vinca alkaloid that interferes with microtubule assembly. The antitumor activity of vinorelbine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Vinorelbine may also interfere with: 1) amino acid, cyclic AMP and glutathione metabolism, 2) calmodulin-dependent Ca++-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis. Vinorelbine inhibited mitotic microtubule formation in intact mouse embryo tectal plates at a concentration of 2 μM inducing a blockade of cells at metaphase, but produced depolymerization of axonal microtubules at a concentration 40 μM, suggesting a modest selectivity of vinorelbine for mitotic microtubules."],"storage_and_handling":["Storage Conditions Store refrigerated between 2° and 8°C (36° and 46°F). Do not freeze. Protect from light. Retain in carton until time of use. Discard unused portion. Unopened vials of Vinorelbine Injection, USP are stable at 25°C (77°F) for up to 72 hours. Store diluted solutions of Vinorelbine Injection, USP at 5° to 30°C (41° to 86°F) [see Dosage and Administration ( 2.3 )] . Vinorelbine Injection, USP is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1 Sterile, Nonpyrogenic, Preservative-free. The container closure is not made with natural rubber latex."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Vinorelbine is a vinca alkaloid that interferes with microtubule assembly. The antitumor activity of vinorelbine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Vinorelbine may also interfere with: 1) amino acid, cyclic AMP and glutathione metabolism, 2) calmodulin-dependent Ca++-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis. Vinorelbine inhibited mitotic microtubule formation in intact mouse embryo tectal plates at a concentration of 2 μM inducing a blockade of cells at metaphase, but produced depolymerization of axonal microtubules at a concentration 40 μM, suggesting a modest selectivity of vinorelbine for mitotic microtubules. 12.3 Pharmacokinetics The pharmacokinetics of vinorelbine were studied in 49 patients who received doses of 30 mg/m 2 administered as 15- to 20-minute constant-rate infusions. Vinorelbine concentrations in plasma decay in a triphasic manner. Distribution Steady-state volume of distribution (V SS ) values range from 25.4 to 40.1 L/kg. Vinorelbine demonstrated high binding to human platelets and lymphocytes. The free fraction was approximately 0.11 in human plasma over a concentration range of 234 to 1169 ng/mL. The binding to plasma constituents in cancer patients ranged from 79.6% to 91.2%. Vinorelbine binding was not altered in the presence of cisplatin, fluorouracil, or doxorubicin. Elimination The terminal phase half-life averages 27.7 to 43.6 hours and the mean plasma clearance ranges from 0.97 to 1.26 L/hr/kg. Metabolism Vinorelbine undergoes substantial hepatic elimination in humans, with large amounts recovered in feces. Two metabolites of vinorelbine have been identified in human blood, plasma and urine; vinorelbine N-oxide and deacetylvinorelbine. Deacetylvinorelbine has been demonstrated to be the primary metabolite of vinorelbine in humans and has been shown to possess antitumor activity similar to vinorelbine. Therapeutic doses of vinorelbine (30 mg/m 2 ) yield very small, if any, quantifiable levels of either metabolite in blood or urine. The metabolism of vinorelbine is mediated by hepatic CYP3A. Excretion After intravenous administration of radioactive vinorelbine, approximately 18% and 46% of administered radioactivity was recovered in urine and feces, respectively. In a different study, 10.9% ± 0.7% of a 30 mg/m 2 intravenous dose was excreted as parent drug in urine. Specific Populations Age has no effect on the pharmacokinetics (CL, V SS and t 1/2 ) of vinorelbine. Drug Interaction Studies The pharmacokinetics of vinorelbine are not influenced by the concurrent administration of cisplatin."],"indications_and_usage":["1 INDICATIONS AND USAGE Vinorelbine Injection is indicated: In combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) As a single agent for the treatment of patients with metastatic NSCLC Vinorelbine Injection is a vinca alkaloid indicated: In combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) ( 1 ) As a single agent for first-line treatment of patients with metastatic NSCLC ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Hepatic Toxicity: Monitor hepatic function prior to initiation and during treatment ( 5.2 ) Severe constipation and bowel obstruction, including necrosis and perforation, occur. Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus ( 5.3 ) Extravasation can result in severe tissue injury, local tissue necrosis and/or thrombophlebitis. Immediately stop vinorelbine and institute recommended management procedures ( 5.4 ) Neurologic Toxicity: Severe sensory and motor neuropathies occur. Monitor patients for new or worsening signs and symptoms of neuropathy. Discontinue for Grade 2 or greater neuropathy ( 5.5 ) Pulmonary toxicity and respiratory failure occur. Interrupt vinorelbine in patients who develop unexplained dyspnea or have any evidence of pulmonary toxicity. Permanently discontinue for confirmed interstitial pneumonitis or ARDS ( 5.6 ) Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of potential risk to the fetus and to use effective contraception ( 5.7 , 8.1 , 8.3 ) 5.1 Myelosuppression Myelosuppression, manifested by neutropenia, anemia and thrombocytopenia, occur in patients receiving vinorelbine as a single agent and in combination with cisplatin [see Adverse Reactions ( 6.1 , 6.2 )] . Neutropenia is the major dose-limiting toxicity with vinorelbine. Grade 3-4 neutropenia occurred in 53% of patients treated with vinorelbine at 30 mg/m 2 per week. Dose adjustment due to myelosuppression occurred in 51% of patients (Study 2). In clinical trials with vinorelbine administered at 30 mg/m 2 per week, neutropenia resulted in hospitalizations for pyrexia and/or sepsis in 8% of patients. Death due to sepsis occurred in 1% of patients. Neutropenia nadirs occur between 7 and 10 days after dosing with neutropenia count recovery usually occurring within the following 7 to 14 days. Monitor complete blood counts prior to each dose of vinorelbine. Do not administer vinorelbine to patients with neutrophil counts <1,000 cells/mm 3 . Adjustments in the dosage of vinorelbine should be based on neutrophil counts obtained on the day of treatment [see Dosage and Administration ( 2.2 )]. 5.2 Hepatic Toxicity Drug-induced liver injury manifest by elevated aspartate aminotransferase (AST) and bilirubin occur in patients receiving vinorelbine as a single agent and in combination with cytotoxic agents. Assess hepatic function prior to initiation of vinorelbine and periodically during treatment. Reduce the dose of vinorelbine for patients who develop elevations in total bilirubin ≥ 2 times upper limit of normal [see Dosage and Administration ( 2.2 ) and Use in Specific Populations ( 8.6 )]. 5.3 Severe Constipation and Bowel Obstruction Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur in patients receiving vinorelbine. Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus, considering adequate dietary fiber intake, hydration and routine use of stool softeners. 5.4 Extravasation and Tissue Injury Extravasation of vinorelbine can result in severe irritation, local tissue necrosis and/or thrombophlebitis. If signs or symptoms of extravasation occur, immediately stop administration of vinorelbine and institute recommended management procedures [see Dosage and Administration ( 2.2 ) and Adverse Reactions ( 6.1 )]. 5.5 Neurologic Toxicity Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving vinorelbine. Monitor patients for new or worsening signs and symptoms of neuropathy, such as paresthesia, hyperesthesia, hyporeflexia and muscle weakness while receiving vinorelbine. Discontinue vinorelbine for CTCAE Grade 2 or greater neuropathy [see Dosage and Administration ( 2.2 ) and Adverse Reactions ( 6.1 )]. 5.6 Pulmonary Toxicity and Respiratory Failure Pulmonary toxicity, including severe acute bronchospasm, interstitial pneumonitis, acute respiratory distress syndrome (ARDS) occur in patients receiving vinorelbine. Interstitial pneumonitis and ARDS included fatalities. The mean time to onset of interstitial pneumonitis and ARDS after vinorelbine administration was one week (range 3 to 8 days) [see Adverse Reactions ( 6.1 )]. Interrupt vinorelbine in patients who develop unexplained dyspnea or have any evidence of pulmonary toxicity. Permanently discontinue vinorelbine for confirmed interstitial pneumonitis or ARDS. 5.7 Embryo-Fetal Toxicity Based on findings from animal studies and its mechanism of action, vinorelbine can cause fetal harm when administered to a pregnant woman. In animal reproduction studies in mice and rabbits, embryo and fetal toxicity were observed with administration of vinorelbine at doses approximately 0.33 and 0.18 times the human therapeutic dose, respectively. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with vinorelbine and for 6 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with vinorelbine and for 3 months after the final dose [see Use in Specific Populations ( 8.1 , 8.3 )]."],"clinical_studies_table":["
Table 7. Efficacy Results (Study 1)
Vinorelbine plus Cisplatin (N=214) Cisplatin (N=218)
Overall Survival
Median Survival in months (95% CI) 7.8 (6.9, 9.6) 6.2 (5.4, 7.7)
Unstratified log-rank p-value 0.01
Overall Response rate (ORR)
Evaluable patients ORR (95% CI) N=206 19% (14%, 25%) N=209 8% (5%, 13%)
Chi-square test p-value <0.001
","
Table 8. Efficacy Results (Study 2)
1n/a = not applicable
Vinorelbine (N=206) Vinorelbine plus cisplatin (N=206) Vindesine plus cisplatin (N=200)
Median survival in months (99.5% CI)7.2 (5.4, 9.1) 9.2 (7.4, 11.1) 7.4 (6.1, 9.1)
Unstratified log-rank p-value n/a10.087
0.05 n/a
Overall Response (ORR) Evaluable Patients ORR (95% CI) N=205 14% (10%, 20%) N=203 28% (22%, 35%) N=198 19% (14%, 25%)
Chi-square test p-value n/a 0.03
< 0.001 n/a
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of vinorelbine has not been studied. Vinorelbine has been shown to affect chromosome number and possibly structure in vivo (polyploidy in bone marrow cells from Chinese hamsters and a positive micronucleus test in mice). It was not mutagenic in the Ames test and gave inconclusive results in the mouse lymphoma TK Locus assay. Vinorelbine did not affect fertility to a statistically significant extent when administered to rats on either a once-weekly (9 mg/m 2 , approximately one third the human dose) or alternate-day schedule (4.2 mg/m 2 , approximately 0.14 times the human recommended dose) prior to and during mating. In male rats, administration of vinorelbine twice weekly for 13 or 26 weeks at dose levels of 2.1 and 7.2 mg/m 2 (approximately 0.07 and 0.24 times the recommended human dose), respectively, resulted in decreased spermatogenesis and prostate/seminal vesicle secretion."],"adverse_reactions_table":["
Table 1: Hematologic Adverse Reactions Experienced in > 5% of Patients Receiving Vinorelbine*†:
*Grade based on modified criteria from the National Cancer Institute version 1.
†Patients with NSCLC had not received prior chemotherapy. The majority of the remaining patients had received prior chemotherapy.
All Patients (N=365) (%)NSCLC (N=143) (%)
Laboratory
Hematologic
Neutropenia < 2,000 cells/mm390 80
< 500 cells/mm336 29
Leukopenia < 4,000 cells/mm392 81
< 1,000 cells/mm315 12
Thrombocytopenia < 100,000 cells/mm35 4
Anemia < 11 g/dl 83 77
< 8 g/dl 9 1
Hospitalizations due to neutropenic complications 9 8
","
Table 2: Non-hematologic Adverse Reactions Experienced in ≥ 5% of Patients Receiving Vinorelbine*†:
*Grade based on modified criteria from the National Cancer Institute version 1.
†Patients with NSCLC had not received prior chemotherapy. The majority of the remaining patients had received prior chemotherapy.
‡ Incidence of paresthesia plus hypesthesia.
All GradesGrade 3-4
All Patients (%)NSCLC (%)All Patients (%)NSCLC (%)
Laboratory
Hepatic
AST increased (N=346) 67 54 6 3
Bilirubin increased (N=351) 13 9 7 5
Clinical
Nausea 44 34 2 1
Asthenia 36 27 7 5
Constipation 35 29 3 2
Injection site reaction 28 38 2 5
Injection site pain 16 13 2 1
Neuropathy peripheral‡25 20 <2 1
Vomiting 20 15 2 1
Diarrhea 17 13 1 1
Alopecia 12 12 ≤1 1
Phlebitis 7 10 <1 1
Dyspnea 7 3 3 2
","
Table 3: Adverse Reactions Experienced by ≥ 10% of Patients on Vinorelbine plus Cisplatin versus Single Agent Cisplatin*
*Graded according to the standard SWOG criteria version 1.
†Categorical toxicity grade not specified
Vinorelbine 25mg/m2 plus Cisplatin 100 mg/m2 (N=212)Cisplatin 100 mg/m2 (N=210)
All Grades (%)Grades 3-4 (%)All Grades (%)Grades 3-4 (%)
Laboratory
Hematologic
Neutropenia 89 82 26 5
Anemia 89 24 72 <8
Leukopenia 88 58 31 <1
Thrombocytopenia 29 5 21 <2
Febrile neutropenia†N/A 11 N/A 0
Renal
Blood creatinine increased 37 4 28 <5
Clinical
Malaise/Fatigue/Lethargy 67 12 49 8
Vomiting 60 13 60 14
Nausea 58 14 57 12
Decreased appetite 46 0 37 0
Constipation 35 3 16 1
Alopecia 34 0 14 0
Weight decreased 34 1 21 <1
Fever without infection 20 2 4 0
Hearing impaired 18 4 18 <4
Injection site reaction 17 <1 1 0
Diarrhea 17 <3 11 <2
Paraesthesia 17 <1 10 <1
Taste alterations 17 0 15 0
Peripheral numbness 11 2 7 <1
Myalgia/Arthralgia 12 <1 3 <1
Phlebitis/Thrombosis/Embolism 10 3 <1 <1
Weakness 12 <3 7 2
Infection 11 <6 <1 <1
Respiratory tract infection 10 <5 3 3
","
Table 4: Adverse Reactions Experienced by ≥ 10 % of Patients from a Comparative Trial of Vinorelbine Plus Cisplatin versus Vindesine Plus Cisplatin versus Single Agent Vinorelbine*
* Grade based on criteria from the World Health Organization (WHO).
† N=194 to 207; all patients receiving vinorelbine/cisplatin with laboratory and non-laboratory data.
‡ N=173 to 192; all patients receiving vindesine/cisplatin with laboratory and non-laboratory data.
§ N=165 to 201; all patients receiving vinorelbine with laboratory and non-laboratory data.
¦ Categorical toxicity grade not specified.
Neurotoxicity includes peripheral neuropathy and constipation.
Vinorelbine/Cisplatin†Vindesine/Cisplatin‡Vinorelbine§
All Grades (%)Grades 3-4 (%)All Grades (%)Grades 3-4 (%)All Grades (%)Grades 3-4 (%)
Laboratory
Hematologic
Neutropenia 95 78 79 48 85 53
Leukopenia 94 57 82 27 83 32
Thrombocytopenia 15 4 10 3.5 3 0
Renal
Blood creatinine increased¦46 N/A 37 N/A 13 N/A
Clinical
Nausea/Vomiting 74 30 72 25 31 2
Alopecia 51 7.5 56 14 30 2
Neurotoxicity44 7 58 17 44 8.5
Diarrhea 25 1.5 24 1 12 0.5
Injection site reaction 17 2.5 7 0 22 2
Ototoxicity 10 2 14 1 1 0
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Myelosuppression Advise patients to contact a healthcare provider for new onset fever, or symptoms of infection [see Warnings and Precautions ( 5.1 )]. Constipation and Bowel Obstruction Advise patients to follow a diet rich in fibers, drink fluids to stay well hydrated and use stool softeners to avoid constipation. Contact a health care provider for severe constipation, new onset abdominal pain, nausea and vomiting [see Warnings and Precautions ( 5.3 )]. Neurologic Toxicity Advise patients to contact a health care provider for new onset or worsening of numbness, tingling, decrease sensation or muscle weakness [see Warnings and Precautions ( 5.5 )]. Pulmonary Toxicity Advise patients to contact a healthcare provider for new onset or worsening of shortness of breath, cough, wheezing or other new pulmonary symptoms [see Warnings and Precautions ( 5.6 )]. Embryo-Fetal Toxicity Advise pregnant women of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 , 8.3 )]. Advise females of reproductive potential to use effective contraception during treatment with Vinorelbine Injection and for 6 months after the final dose [see Use in Specific Populations ( 8.3 )]. Advise males with female partners of reproductive potential to use effective contraception during treatment with Vinorelbine Injection and for 3 months after the final dose [see Use in Specific Populations ( 8.3 ) and Nonclinical Toxicology ( 13.1 )]. Lactation Advise women not to breastfeed during treatment with Vinorelbine Injection and for 9 days after the final dose [see Use in Specific Populations ( 8.2 )]. Infertility Advise males of reproductive potential that Vinorelbine Injection may impair fertility [see Use in Specific Populations ( 8.3 )]. SAGENT ® Mfd. for SAGENT Pharmaceuticals Schaumburg, IL 60195 (USA) Made in China ©2023 Sagent Pharmaceuticals Revised: September 2023 SAGENT Pharmaceuticals ®"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION In combination with cisplatin: 25 to 30 mg/m 2 as an intravenous injection or infusion once weekly ( 2.1 ) Single agent: 30 mg/m 2 as intravenously once a week ( 2.1 ) Adjust dose in patients with decreased neutrophil counts or elevated serum total bilirubin ( 2.2 ) 2.1 Recommended Dosage In Combination with Cisplatin 100 mg/m 2 The recommended dosage of Vinorelbine Injection is 25 mg/m 2 administered as an intravenous injection or infusion over 6 to 10 minutes on Days 1, 8, 15 and 22 of a 28-day cycle in combination with cisplatin 100 mg/m 2 on Day 1 only of each 28-day cycle. In Combination with Cisplatin 120 mg/m 2 The recommended dosage of Vinorelbine Injection is 30 mg/m 2 administered as an intravenous injection or infusion over 6 to 10 minutes once a week in combination with cisplatin 120 mg/m 2 on Days 1 and 29, then every 6 weeks. Single Agent The recommended dosage of Vinorelbine Injection is 30 mg/m 2 administered intravenously over 6 to 10 minutes once a week. 2.2 Dosage Modifications Myelosuppression Hold or decrease the dose of Vinorelbine Injection in patients with decreased neutrophil counts according to the following schema [see Warnings and Precautions ( 5.1 )]: Neutrophils on Day of Treatment (cells/mm 3 ) Percentage of Starting Dose of Vinorelbine Injection ≥ 1,500 100% 1,000 to 1,499 50% < 1,000 Do not administer Vinorelbine Injection. Repeat neutrophil count in one week. If three consecutive weekly doses are held because neutrophil count is < 1,000 cells/mm 3 , discontinue Vinorelbine Injection Note: For patients who experience fever and/or sepsis while neutrophil count is < 1,500 cells/mm 3 or had 2 consecutive weekly doses held due to neutropenia, subsequent doses of Vinorelbine Injection should be: > 1,500 75% 1,000 to 1,499 37.5% < 1,000 Do not administer Vinorelbine Injection. Repeat neutrophil count in one week. Hepatic Impairment/Toxicity Reduce Vinorelbine Injection dose in patients with elevated serum total bilirubin concentration according to the following schema [see Warnings and Precautions ( 5.2 ) and Use in Specific Populations ( 8.6 )] : Serum Total Bilirubin Concentration (mg/dl) Percentage of Starting Dose of Vinorelbine Injection ≤ 2.0 100% 2.1 to 3.0 50% > 3.0 25% Concurrent Myelosuppression and Hepatic Impairment/Toxicity In patients with both myelosuppression and hepatic impairment/toxicity, administer the lower of the doses based on the corresponding starting dose of Vinorelbine Injection determined from the above schemas. Neurologic Toxicity Discontinue Vinorelbine Injection for Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 or higher peripheral neuropathy or autonomic neuropathy causing constipation [see Warnings and Precautions ( 5.5 )]. 2.3 Preparation and Administration Preparation Dilute Vinorelbine Injection in an intravenous bag to a concentration between 0.5 mg/mL and 2 mg/mL. Use one of the following recommended solutions for dilution: 5% Dextrose Injection, USP 0.9% Sodium Chloride Injection, USP 0.45% Sodium Chloride Injection, USP 5% Dextrose and 0.45% Sodium Chloride Injection, USP Ringer's Injection, USP Lactated Ringer's Injection, USP Stability and Storage Conditions of Diluted Solutions Diluted Vinorelbine Injection may be used for up to 24 hours under normal room light when stored in polyvinyl chloride bags at 5° to 30°C (41° to 86°F). Administration Administer diluted Vinorelbine Injection over 6 to 10 minutes into the side port of a free-flowing intravenous line followed by flushing with at least 75 to 125 mL of one of the solutions. Vinorelbine Injection must only be administered intravenously. It is extremely important that the intravenous needle or catheter be properly positioned before any Vinorelbine Injection is injected. Parenteral drug products should be visually inspected for particulate matter and discoloration prior to administration whenever solution and container permit. If particulate matter is seen, Vinorelbine Injection should not be administered. Management of Suspected Extravasation If Vinorelbine Injection leakage into surrounding tissue occurs or is suspected, immediately stop administration of Vinorelbine Injection and initiate appropriate management measures in accordance with institutional policies [see Warnings and Precautions ( 5.4 )]. 2.4 Procedures for Proper Handling and Disposal Vinorelbine Injection is a cytotoxic drug. Follow applicable special handling and disposal procedures 1 . Exercise caution in handling and preparing the solution of Vinorelbine Injection. The use of gloves is recommended. If the solution of Vinorelbine Injection contacts the skin or mucosa, immediately wash the skin or mucosa thoroughly with soap and water. Avoid contamination of the eye with Vinorelbine Injection. If exposure occurs, flush the eyes with water immediately and thoroughly. Discard unused portion."],"spl_product_data_elements":["Vinorelbine Vinorelbine vinorelbine tartrate vinorelbine water"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Vinorelbine Injection, USP: 1 mL (10 mg per 1 mL) and 5 mL (50 mg per 5 mL) clear colorless to pale yellow solution in single-dose vial. Vinorelbine Injection: 10 mg per 1 mL and 50 mg per 5 mL in single-dose vial ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation: Advise not to breastfeed ( 8.2 ) 8.1 Pregnancy Risk Summary Based on findings from animal studies and its mechanism of action [see Clinical Pharmacology ( 12.1 )] , vinorelbine can cause fetal harm when administered to a pregnant woman. Available human data are insufficient to inform the drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies in mice and rabbits, embryo and fetal toxicity were observed with administration of vinorelbine at doses approximately 0.33 and 0.18 times the human therapeutic dose, respectively (see Data ) . Advise pregnant women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2 to 4% and 15 to 20%, respectively. Data Animal Data In a mouse embryo-fetal development study, administration of a single dose of vinorelbine at a dose level of 9 mg/m 2 or greater (approximately 0.33 times the recommended human dose based on body surface area) was embryotoxic and fetotoxic. Vinorelbine was embryotoxic and fetotoxic to pregnant rabbits when administered every 6 days during the period of organogenesis at doses of 5.5 mg/m 2 (approximately 0.18 times the recommended human dose based on body surface area) or greater. At doses that did not cause maternal toxicity in either species, vinorelbine administration resulted in reduced fetal weight and delayed ossification. 8.2 Lactation Risk Summary There are no data on the presence of vinorelbine in human milk or its effects on the breastfed infant or on milk production. Because of the potential for serious adverse reactions in breastfed infants from vinorelbine, advise women not to breastfeed during treatment with vinorelbine and for 9 days after the final dose. 8.3 Females and Males of Reproductive Potential Pregnancy Testing Verify pregnancy status in females of reproductive potential prior to initiating vinorelbine [see Use in Specific Populations ( 8.1 )]. Contraception Females Vinorelbine can cause fetal harm when administered to pregnant women [see Use in Specific Populations ( 8.1 )] . Advise female patients of reproductive potential to use effective contraception during treatment with vinorelbine and for 6 months after the final dose. Males Vinorelbine may damage spermatozoa [see Nonclinical Toxicology ( 13.1 )]. Advise males with female sexual partners of reproductive potential to use effective contraception during treatment with vinorelbine and for 3 months after the final dose. Infertility Males Based on animal findings, vinorelbine may impair fertility in males [see Nonclinical Toxicology ( 13.1 )]. 8.4 Pediatric Use The safety and effectiveness of vinorelbine in pediatric patients have not been established. Results from a single-arm study of vinorelbine administered at the dose of 33.75 mg/m 2 (for 35 patients) or at the dose of 30 mg/m 2 (for 11 patients) every week for 6 weeks followed by 2 weeks of rest were evaluated (courses of 8 weeks). Forty-six patients age 1 to 25 (median 11 years) with recurrent solid malignant tumors, including rhabdomyosarcoma or undifferentiated sarcoma (N=21 patients), neuroblastoma (N= 4 patients) and central nervous system (CNS) tumors (N=21 patients), were enrolled. The most significant grade 3 or 4 hematological adverse reactions were neutropenia (70%) and anemia (33%). The most significant grade 3 or 4 non-hematological adverse reactions were motor (15%) or cranial (13%) neuropathy, hypoxia (13%) and dyspnea (11%). Objective tumor response was observed in 2 out of 21 patients with rhabdomyosarcoma or undifferentiated sarcoma. No objective tumor response was observed in patients with CNS tumors (N=21) or neuroblastoma (N=4). 8.5 Geriatric Use Of the 769 number of patients who received vinorelbine as a single agent and in combination with cisplatin in studies 1, 2 and 3, 247 patients were 65 years of age or older. No overall differences in safety, efficacy and pharmacokinetic parameters were observed between these patients and younger patients [see Clinical Pharmacology ( 12.3 )] . 8.6 Hepatic Impairment The influence of hepatic impairment on the pharmacokinetics of vinorelbine has not been evaluated, but the liver plays an important role in the metabolism of vinorelbine. Elevated AST occurs in >60% of the patients receiving vinorelbine as a single agent (6% Grade 3-4). Therefore, exercise caution in patients with hepatic impairment. Reduce the dose of vinorelbine for patients with elevated serum total bilirubin concentrations [see Dosage and Administration ( 2.2 ) and Warnings and Precautions ( 5.2 )] ."],"dosage_and_administration_table":["
Neutrophils on Day of Treatment (cells/mm3)Percentage of Starting Dose of Vinorelbine Injection
≥ 1,500 100%
1,000 to 1,499 50%
< 1,000 Do not administer Vinorelbine Injection. Repeat neutrophil count in one week. If three consecutive weekly doses are held because neutrophil count is < 1,000 cells/mm3, discontinue Vinorelbine Injection
Note: For patients who experience fever and/or sepsis while neutrophil count is < 1,500 cells/mm3 or had 2 consecutive weekly doses held due to neutropenia, subsequent doses of Vinorelbine Injection should be:
> 1,500 75%
1,000 to 1,499 37.5%
< 1,000 Do not administer Vinorelbine Injection. Repeat neutrophil count in one week.
","
Serum Total Bilirubin Concentration (mg/dl)Percentage of Starting Dose of Vinorelbine Injection
≤ 2.0 100%
2.1 to 3.0 50%
> 3.0 25%
"],"package_label_principal_display_panel":["PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label NDC 25021-204-01 VINORELBINE INJECTION, USP 10 mg per mL Rx only 1 mL Single-Dose Vial Must Be Diluted For Intravenous Use Only Caution: Cytotoxic Agent PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label","PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label NDC 25021-204-05 VINORELBINE INJECTION, USP 50 mg per 5 mL (10 mg per mL) Rx only 5 mL Single-Dose Vial Must Be Diluted For Intravenous Use Only Caution: Cytotoxic Agent PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of vinorelbine has not been studied. Vinorelbine has been shown to affect chromosome number and possibly structure in vivo (polyploidy in bone marrow cells from Chinese hamsters and a positive micronucleus test in mice). It was not mutagenic in the Ames test and gave inconclusive results in the mouse lymphoma TK Locus assay. Vinorelbine did not affect fertility to a statistically significant extent when administered to rats on either a once-weekly (9 mg/m 2 , approximately one third the human dose) or alternate-day schedule (4.2 mg/m 2 , approximately 0.14 times the human recommended dose) prior to and during mating. In male rats, administration of vinorelbine twice weekly for 13 or 26 weeks at dose levels of 2.1 and 7.2 mg/m 2 (approximately 0.07 and 0.24 times the recommended human dose), respectively, resulted in decreased spermatogenesis and prostate/seminal vesicle secretion."]},"tags":[{"label":"Vinca Alkaloid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Substance-K receptor","category":"target"},{"label":"TACR2","category":"gene"},{"label":"CYP3A4","category":"gene"},{"label":"TUBB","category":"gene"},{"label":"L01CA04","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Non-small cell lung cancer","category":"indication"},{"label":"Pierre Fabre","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Antimitotic Agents","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antineoplastic Agents, Phytogenic","category":"pharmacology"},{"label":"Tubulin Modulators","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":["WARNING: MYELOSUPPRESSION Severe myelosuppression resulting in serious infection, septic shock, hospitalization and death can occur [see Warnings and Precautions ( 5.1 )]. Decrease the dose or withhold vinorelbine in accord with recommended dose modifications [see Dosage and Administration ( 2.2 )]. WARNING: MYELOSUPPRESSION See full prescribing information for complete boxed warning. Severe myelosuppression resulting in serious infection, septic shock, and death can occur ( 5.1 ). Decrease the dose or withhold vinorelbine in accord with recommended dose modifications ( 2.2 )."],"safetySignals":[{"date":"","signal":"DISEASE PROGRESSION","source":"FDA FAERS","actionTaken":"761 reports"},{"date":"","signal":"MALIGNANT NEOPLASM PROGRESSION","source":"FDA FAERS","actionTaken":"694 reports"},{"date":"","signal":"NEUTROPENIA","source":"FDA FAERS","actionTaken":"658 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"639 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"502 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"501 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"481 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"446 reports"},{"date":"","signal":"ANAEMIA","source":"FDA FAERS","actionTaken":"444 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"393 reports"}],"drugInteractions":[{"url":"/drug/fluconazole","drug":"fluconazole","action":"Avoid combination","effect":"May interact with Fluconazole, Vinorelbine Tartrate","source":"DrugCentral","drugSlug":"fluconazole"},{"url":"/drug/ketoconazole","drug":"ketoconazole","action":"Avoid combination","effect":"May interact with Ketoconazole, Vinorelbine Tartrate","source":"DrugCentral","drugSlug":"ketoconazole"},{"url":"/drug/voriconazole","drug":"voriconazole","action":"Avoid combination","effect":"May interact with Vinorelbine Tartrate, Voriconazole","source":"DrugCentral","drugSlug":"voriconazole"}],"commonSideEffects":[{"effect":"Leukopenia","drugRate":"≥20%","severity":"serious","_validated":true},{"effect":"Neutropenia","drugRate":"≥20%","severity":"serious","_validated":true},{"effect":"Anemia","drugRate":"≥20%","severity":"serious","_validated":true},{"effect":"Increased aspartate aminotransferase","drugRate":"≥20%","severity":"serious","_validated":true},{"effect":"Nausea","drugRate":"≥20%","severity":"serious","_validated":true},{"effect":"Vomiting","drugRate":"≥20%","severity":"serious","_validated":true},{"effect":"Constipation","drugRate":"≥20%","severity":"serious","_validated":true},{"effect":"Asthenia","drugRate":"≥20%","severity":"serious","_validated":true},{"effect":"Injection site reaction","drugRate":"≥20%","severity":"serious","_validated":true},{"effect":"Peripheral neuropathy","drugRate":"≥20%","severity":"serious","_validated":true},{"effect":"Increased total bilirubin","drugRate":"≥5%","severity":"common","_validated":true},{"effect":"Increased AST","drugRate":"≥5%","severity":"common","_validated":true},{"effect":"Paresthesia","drugRate":"reported","severity":"mild"},{"effect":"Hypesthesia","drugRate":"reported","severity":"mild"},{"effect":"Diarrhea","drugRate":"reported","severity":"mild"},{"effect":"Alopecia","drugRate":"reported","severity":"mild"},{"effect":"Phlebitis","drugRate":"reported","severity":"mild"},{"effect":"Dyspnea","drugRate":"reported","severity":"mild"}],"contraindications":["Bone marrow depression","Breastfeeding (mother)","Disorder of lung","Gastrointestinal obstruction","Gastrointestinal perforation","Hepatic Metastases","Hepatic failure","Infectious disease","Interstitial pneumonia","Intestinal Ischemic Necrosis","Intestinal obstruction","Leukopenia","Pregnancy, function","Severe Granulocytopenia"],"specialPopulations":{"Pregnancy":"Vinorelbine can cause fetal harm when administered to pregnant woman. Available human data are insufficient to inform the drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies in mice and rabbits, embryo and fetal toxicity were observed with administration of vinorelbine at doses approximately 0.33 and 0.18 times the human therapeutic dose, respectively. Advise pregnant women of the potential risk to fetus.","Geriatric use":"Of the 769 number of patients who received vinorelbine as single agent and in combination with cisplatin in studies 1, and 3, 247 patients were 65 years of age or older. No overall differences in safety, efficacy and pharmacokinetic parameters were observed between these patients and younger patients.","Paediatric use":"The safety and effectiveness of vinorelbine in pediatric patients have not been established. Results from single-arm study of vinorelbine administered at the dose of 33.75 mg/m2 (for 35 patients) or at the dose of 30 mg/m2 (for 11 patients) every week for weeks followed by weeks of rest were evaluated (courses of weeks). Forty-six patients age to 25 (median 11 years) with recurrent solid malignant tumors, including rhabdomyosarcoma or undifferentiated sarcoma (N=21 patients), were treated with vinorelbine."}},"trials":[],"aliases":[],"company":"Pierre Fabre","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=vinorelbine","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:45:45.980729+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:45:55.859961+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:45:45.106341+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=vinorelbine","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:45:56.189793+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:45:43.976776+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"WARNING: MYELOSUPPRESSION Severe myelosuppression resulting in serious infection, septic shock, hospitalization and death can occur [see Warnings and Precautions ( 5.1 )]. Decrease the dose or withhold vinorelbine in accord with recommended dose modifications [see Dosage and Administration ( 2.2 )]. WARNING: MYELOSUPPRESSION See full prescribing information for complete boxed warning. Severe myelosuppression resulting in serious infection, septic shock, and death can occur ( 5.1 ). Decrease the ","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:45:43.976816+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:45:57.723280+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL553025/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:45:56.951371+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA091106","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:45:43.976821+00:00"}},"allNames":"navelbine","offLabel":[],"synonyms":["vinorelbin ditartrate","noranhydrovinblastine tartrate","vinorelbine","navelbin","navelbine base","5'-anhydrovinblastine","vinorelbine tartrate","vinorelbine ditartrate","navelbine","vinorelbine base"],"timeline":[{"date":"1994-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from PIERRE FABRE to Pierre Fabre"},{"date":"1994-12-23","type":"positive","source":"DrugCentral","milestone":"FDA approval (Pierre Fabre)"},{"date":"2005-04-18","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 3 manufacturers approved"}],"aiSummary":"Navelbine (vinorelbine) is a vinca alkaloid chemotherapy medication originally developed by Pierre Fabre. It targets the Substance-K receptor and is used to treat non-small cell lung cancer. Navelbine is a small molecule with a half-life of 26 hours and bioavailability of 27%. The medication is off-patent, with multiple generic manufacturers available. It was FDA-approved in 1994.","approvals":[{"date":"1994-12-23","orphan":false,"company":"PIERRE FABRE","regulator":"FDA"}],"brandName":"Navelbine","ecosystem":[{"indication":"Non-small cell lung cancer","otherDrugs":[{"name":"alectinib","slug":"alectinib","company":"Hoffman-La Roche"},{"name":"brigatinib","slug":"brigatinib","company":"Ariad"},{"name":"ceritinib","slug":"ceritinib","company":"Novartis Pharms Corp"},{"name":"crizotinib","slug":"crizotinib","company":"Pf Prism Cv"}],"globalPrevalence":2200000}],"mechanism":{"target":"Substance-K receptor","novelty":"Follow-on","targets":[{"gene":"TACR2","source":"DrugCentral","target":"Substance-K receptor","protein":"Substance-K receptor"},{"gene":"CYP3A4","source":"DrugCentral","target":"Cytochrome P450 3A4","protein":"Cytochrome P450 3A4"},{"gene":"TUBB","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta chain"},{"gene":"TUBB1","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta-1 chain"},{"gene":"TUBB2A","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta-2A chain"},{"gene":"TUBB2B","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta-2B chain"},{"gene":"TUBB3","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta-3 chain"},{"gene":"TUBB4A","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta-4A chain"},{"gene":"TUBB4B","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta-4B chain"},{"gene":"TUBB6","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta-6 chain"}],"modality":"Small Molecule","drugClass":"Vinca Alkaloid","explanation":"Vinorelbine is vinca alkaloid that interferes with microtubule assembly. The antitumor activity of vinorelbine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Vinorelbine may also interfere with: 1) amino acid, cyclic AMP and glutathione metabolism, 2) calmodulin-dependent Ca++-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis. Vinorelbine inhibited mitotic microtubule formation in intact mouse embryo tectal plates at concentration of uM inducing blockade of cells at metaphase, but produced depolymerization of axonal microtubules at concentration 40 uM, suggesting modest selectivity of vinorelbine for mitotic microtubules.","oneSentence":"Navelbine works by binding to the Substance-K receptor, disrupting microtubule formation and inhibiting cell division.","technicalDetail":"Navelbine binds to the vinca domain of tubulin, a protein subunit of microtubules, thereby inhibiting microtubule polymerization and cell division.","_target_confidence":0.5},"commercial":{"launchDate":"1994","_launchSource":"DrugCentral (FDA 1994-12-23, PIERRE FABRE)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2827","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=vinorelbine","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=vinorelbine","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T16:14:15.278937","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:46:01.590238+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"vinblastine","drugSlug":"vinblastine","fdaApproval":"1965-11-05","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"vincristine","drugSlug":"vincristine","fdaApproval":"1963-07-10","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"vinorelbine","indications":{"approved":[{"name":"Non-small cell lung cancer","source":"DrugCentral","snomedId":254637007,"regulator":"FDA","usPrevalence":236000,"globalPrevalence":2200000,"prevalenceMethod":"curated","prevalenceSource":"IARC GLOBOCAN, 2022"}],"offLabel":[{"name":"Kaposi's sarcoma","source":"DrugCentral","drugName":"vinorelbine","evidenceCount":16,"evidenceLevel":"moderate"},{"name":"Metastatic Breast Carcinoma","source":"DrugCentral","drugName":"vinorelbine"},{"name":"Neoplasm of endometrium","source":"DrugCentral","drugName":"vinorelbine","evidenceCount":5,"evidenceLevel":"emerging"},{"name":"Small cell carcinoma of lung","source":"DrugCentral","drugName":"vinorelbine"}],"pipeline":[]},"currentOwner":"Pierre Fabre","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"vinblastine","brandName":"vinblastine","genericName":"vinblastine","approvalYear":"1965","relationship":"same-class"},{"drugId":"vincristine","brandName":"vincristine","genericName":"vincristine","approvalYear":"1963","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02567435","phase":"PHASE3","title":"Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-06-01","conditions":["Alveolar Rhabdomyosarcoma","Botryoid-Type Embryonal Rhabdomyosarcoma","Embryonal Rhabdomyosarcoma","Rhabdomyosarcoma","Sclerosing Rhabdomyosarcoma","Spindle Cell Rhabdomyosarcoma"],"enrollment":325,"completionDate":"2026-10-27"},{"nctId":"NCT06459180","phase":"PHASE3","title":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-24","conditions":["Cervical Cancer"],"enrollment":686,"completionDate":"2028-06-15"},{"nctId":"NCT05999994","phase":"PHASE2","title":"A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2020-01-22","conditions":["Neoplasms","Child","Adolescent"],"enrollment":105,"completionDate":"2027-05"},{"nctId":"NCT05806060","phase":"PHASE3","title":"Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-04-25","conditions":["Triple-Negative Breast Cancer"],"enrollment":134,"completionDate":"2026-11-01"},{"nctId":"NCT04881838","phase":"PHASE3","title":"CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2021-03-01","conditions":["Pediatric Anaplastic Large Cell Lymphoma"],"enrollment":172,"completionDate":"2029-03-01"},{"nctId":"NCT07021989","phase":"PHASE2","title":"ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Michael Spinner, MD","startDate":"2026-05-01","conditions":["Hodgkin Lymphoma, Adult","Refractory Hodgkin Lymphoma","Classic Hodgkin Lymphoma"],"enrollment":38,"completionDate":"2033-10-31"},{"nctId":"NCT07203729","phase":"PHASE2","title":"The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-03-01","conditions":["HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis"],"enrollment":184,"completionDate":"2030-12-30"},{"nctId":"NCT06875128","phase":"PHASE2","title":"Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease","status":"RECRUITING","sponsor":"Delcath Systems Inc.","startDate":"2026-01-29","conditions":["Metastatic Breast Cancer in the Liver"],"enrollment":90,"completionDate":"2029-08"},{"nctId":"NCT07466316","phase":"PHASE3","title":"A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-22","conditions":["Rhabdomyosarcoma"],"enrollment":342,"completionDate":"2031-03-31"},{"nctId":"NCT07461454","phase":"PHASE3","title":"YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2026-03-10","conditions":["Locally Advanced or Metastatic Breast Cancer"],"enrollment":376,"completionDate":"2028-06-30"},{"nctId":"NCT07450508","phase":"PHASE3","title":"Study of Bendamustine, Gemcitabine and Vinorelbine Regimen in Relapsed/Refractory Classical Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Cairo University","startDate":"2024-04-30","conditions":["Classical Hodgkin Lymphoma Relapsed"],"enrollment":88,"completionDate":"2026-02-01"},{"nctId":"NCT06632327","phase":"PHASE3","title":"Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2024-12-11","conditions":["Resectable Lung Non-Small Cell Carcinoma","Stage II Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8"],"enrollment":1100,"completionDate":"2030-04-30"},{"nctId":"NCT04486391","phase":"PHASE3","title":"Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma","status":"TERMINATED","sponsor":"BeiGene","startDate":"2020-12-14","conditions":["Classical Hodgkin Lymphoma"],"enrollment":3,"completionDate":"2025-10-13"},{"nctId":"NCT04697628","phase":"PHASE3","title":"Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer","status":"COMPLETED","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2021-02-22","conditions":["Cervical Cancer"],"enrollment":502,"completionDate":"2026-01-15"},{"nctId":"NCT07420439","phase":"PHASE2","title":"Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease","status":"NOT_YET_RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2026-05-15","conditions":["Non Small Cell Lung Cancer Metastatic","Interstitial Lung Disease (ILD)"],"enrollment":108,"completionDate":"2028-11-15"},{"nctId":"NCT04994132","phase":"PHASE3","title":"A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2021-09-14","conditions":["Alveolar Rhabdomyosarcoma","Botryoid-Type Embryonal Rhabdomyosarcoma","Embryonal Rhabdomyosarcoma","Metastatic Embryonal Rhabdomyosarcoma","Metastatic Rhabdomyosarcoma","Solid Alveolar Rhabdomyosarcoma","Spindle Cell Rhabdomyosarcoma","Spindle Cell/Sclerosing Rhabdomyosarcoma"],"enrollment":118,"completionDate":"2026-06-30"},{"nctId":"NCT02000622","phase":"PHASE3","title":"Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-03-27","conditions":["Breast Cancer Metastatic","BRCA 1 Gene Mutation","BRCA 2 Gene Mutation"],"enrollment":302,"completionDate":"2025-12-23"},{"nctId":"NCT07406542","phase":"PHASE3","title":"A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2026-04-01","conditions":["Recurrent or Metastatic Breast Cancer"],"enrollment":400,"completionDate":"2030-04-01"},{"nctId":"NCT06435429","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Jazz Pharmaceuticals","startDate":"2024-08-13","conditions":["Metastatic HER2-positive Breast Cancer"],"enrollment":550,"completionDate":"2030-10-18"},{"nctId":"NCT04639986","phase":"PHASE3","title":"Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2020-11-23","conditions":["Metastatic Breast Cancer"],"enrollment":331,"completionDate":"2026-12"},{"nctId":"NCT02486718","phase":"PHASE3","title":"Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2015-10-31","conditions":["Non-Small Cell Lung Cancer"],"enrollment":1280,"completionDate":"2027-08-31"},{"nctId":"NCT05104866","phase":"PHASE3","title":"A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-10-18","conditions":["Breast Cancer"],"enrollment":732,"completionDate":"2026-07-31"},{"nctId":"NCT07007559","phase":"PHASE1,PHASE2","title":"ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies","status":"RECRUITING","sponsor":"ALX Oncology Inc.","startDate":"2025-04-28","conditions":["Breast Cancer, Metastatic"],"enrollment":80,"completionDate":"2027-12"},{"nctId":"NCT07047365","phase":"PHASE3","title":"TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-07-25","conditions":["HER2-positive Advanced Breast Cancer"],"enrollment":416,"completionDate":"2028-12"},{"nctId":"NCT03456076","phase":"PHASE3","title":"A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-08-16","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":257,"completionDate":"2026-11-19"},{"nctId":"NCT04648033","phase":"PHASE1","title":"Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-12-07","conditions":["Locally Advanced Non-Small Cell Lung Cancer"],"enrollment":21,"completionDate":"2023-10-02"},{"nctId":"NCT05300282","phase":"PHASE1,PHASE2","title":"Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2023-02-27","conditions":["Relapsed or Refractory Hodgkin's Lymphoma"],"enrollment":122,"completionDate":"2030-04-27"},{"nctId":"NCT07371910","phase":"PHASE3","title":"Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-06-12","conditions":["Metastatic Breast Cancer","HRD-Positive/HER2-Negative Advanced Breast Cancer"],"enrollment":200,"completionDate":"2031-03"},{"nctId":"NCT06564844","phase":"PHASE3","title":"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-10-15","conditions":["Non-small Cell Lung Cancer"],"enrollment":24,"completionDate":"2027-06-30"},{"nctId":"NCT05553782","phase":"EARLY_PHASE1","title":"Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-11-01","conditions":["Salivary Gland Cancer","Adenoid Cystic Carcinoma of the Salivary Gland","Squamous Cell Carcinoma of Head and Neck","Head and Neck Cancer"],"enrollment":30,"completionDate":"2029-08-01"},{"nctId":"NCT06519370","phase":"PHASE3","title":"FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","startDate":"2024-08-09","conditions":["Triple Negative Breast Cancer"],"enrollment":350,"completionDate":"2027-06-20"},{"nctId":"NCT06576635","phase":"NA","title":"LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2024-12-16","conditions":["NSCLC"],"enrollment":29,"completionDate":"2026-09"},{"nctId":"NCT02813135","phase":"PHASE1,PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":["Pediatric Cancer"],"enrollment":472,"completionDate":"2031-02"},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":["Breast Cancer","ER-positive Breast Cancer","HER2-negative Breast Cancer","Metastatic Breast Cancer"],"enrollment":24,"completionDate":"2029-07-31"},{"nctId":"NCT06908304","phase":"PHASE3","title":"A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC","status":"RECRUITING","sponsor":"Maia Biotechnology","startDate":"2025-12-08","conditions":["Carcinoma, Non-Small -Cell Lung"],"enrollment":300,"completionDate":"2027-12-31"},{"nctId":"NCT02998528","phase":"PHASE3","title":"A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-03-04","conditions":["Non Small Cell Lung Cancer"],"enrollment":505,"completionDate":"2024-12-06"},{"nctId":"NCT06072612","phase":"PHASE3","title":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","status":"RECRUITING","sponsor":"BriaCell Therapeutics Corporation","startDate":"2023-12-05","conditions":["Breast Cancer","Metastatic Breast Cancer","Breast Neoplasm","Breast Cancer Metastatic","End Stage Cancer"],"enrollment":404,"completionDate":"2028-06"},{"nctId":"NCT06690840","phase":"PHASE2","title":"Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients","status":"RECRUITING","sponsor":"European Institute of Oncology","startDate":"2025-03-06","conditions":["Triple Negative Breast Cancer"],"enrollment":45,"completionDate":"2027-02-15"},{"nctId":"NCT06908993","phase":"PHASE3","title":"Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated","status":"RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2025-12-09","conditions":["Advanced Non Small Cell Lung Cancer","MET Exon 14 Mutation"],"enrollment":133,"completionDate":"2028-07-15"},{"nctId":"NCT04765709","phase":"PHASE2","title":"Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-09-24","conditions":["Non-small Cell Lung Cancer Stage III"],"enrollment":10,"completionDate":"2025-01-30"},{"nctId":"NCT07088263","phase":"PHASE3","title":"Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-09-15","conditions":["Breast Neoplasms"],"enrollment":192,"completionDate":"2028-06-24"},{"nctId":"NCT05583110","phase":"PHASE2","title":"Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2023-03-08","conditions":["HER2-positive Metastatic Breast Cancer","Locally Advanced HER2 Positive Breast Carcinoma"],"enrollment":13,"completionDate":"2025-05-30"},{"nctId":"NCT05347134","phase":"PHASE3","title":"SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2022-06-10","conditions":["Triple Negative Breast Cancer"],"enrollment":254,"completionDate":"2027-06-30"},{"nctId":"NCT04145349","phase":"PHASE1,PHASE2","title":"CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2020-01-22","conditions":["Desmoplastic Small Round Cell Tumor"],"enrollment":30,"completionDate":"2026-10"},{"nctId":"NCT06081959","phase":"PHASE3","title":"Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2023-10-31","conditions":["Metastatic Breast Cancer"],"enrollment":376,"completionDate":"2027-12-31"},{"nctId":"NCT03618550","phase":"PHASE2","title":"Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-08-01","conditions":["Hodgkin Lymphoma","Relapsed or Refractory Hodgkin Lymphoma"],"enrollment":257,"completionDate":"2026-08"},{"nctId":"NCT04388839","phase":"PHASE2","title":"Evolutionary Therapy for Rhabdomyosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2020-12-29","conditions":["Rhabdomyosarcoma"],"enrollment":12,"completionDate":"2027-08"},{"nctId":"NCT06230055","phase":"PHASE4","title":"Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-01-05","conditions":["HER2-negative Breast Cancer","Leptomeningeal Metastasis"],"enrollment":37,"completionDate":"2027-01-01"},{"nctId":"NCT06081400","phase":"NA","title":"Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful Waiting","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2024-03-04","conditions":["Desmoid Tumor"],"enrollment":150,"completionDate":"2029-06"},{"nctId":"NCT06382142","phase":"PHASE3","title":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-06-21","conditions":["Triple-Negative Breast Cancer"],"enrollment":418,"completionDate":"2026-06"},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":["Salivary Gland Carcinoma","Precision Therapy"],"enrollment":39,"completionDate":"2028-07-10"},{"nctId":"NCT06079983","phase":"PHASE3","title":"JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects","status":"RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2023-12-01","conditions":["Breast Cancer"],"enrollment":400,"completionDate":"2029-03-01"},{"nctId":"NCT02514681","phase":"PHASE3","title":"A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer","status":"COMPLETED","sponsor":"Japan Breast Cancer Research Group","startDate":"2015-08-01","conditions":["HER2-positive Locally Advanced or Metastatic Breast Cancer"],"enrollment":226,"completionDate":"2022-08-10"},{"nctId":"NCT04759248","phase":"PHASE2","title":"Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2021-03-15","conditions":["Breast Cancer"],"enrollment":55,"completionDate":"2027-07-01"},{"nctId":"NCT05063786","phase":"PHASE3","title":"Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Breast Cancer Research Group","startDate":"2021-09-14","conditions":["Advanced Breast Cancer"],"enrollment":27,"completionDate":"2026-06"},{"nctId":"NCT07137884","phase":"PHASE2","title":"Anlotinib Hydrochloride Capsules in Maintenance Treatment for Intermediate-High Risk Rhabdomyosarcoma in Children","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-10-01","conditions":["Rhabdomyosarcoma Recurrent","Maintenance Treatment"],"enrollment":150,"completionDate":"2028-12-30"},{"nctId":"NCT07131345","phase":"PHASE1,PHASE2","title":"Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Center, China","startDate":"2025-09-01","conditions":["Malignant Mesothelioma","Mesothelioma"],"enrollment":55,"completionDate":"2027-07-01"},{"nctId":"NCT06023641","phase":"PHASE2","title":"Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-03-13","conditions":["Rhabdomyosarcoma"],"enrollment":135,"completionDate":"2037-10"},{"nctId":"NCT06255392","phase":"PHASE3","title":"Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-06-12","conditions":["Fludzoparib" and Anti-angiogenic","HRD-positive/HER2-negative Advanced Breast Cancer"],"enrollment":200,"completionDate":"2031-03"},{"nctId":"NCT03482362","phase":"PHASE2","title":"Vinorelbine in Advanced BRAF-like Colon Cancer","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2018-03-01","conditions":["Colon Cancer"],"enrollment":1,"completionDate":"2020-03-17"},{"nctId":"NCT06500494","phase":"","title":"To Describe How Well Vinorelbine Given Orally Works in Patients With a Breast Cancer After 2 Years of Treatment","status":"RECRUITING","sponsor":"Pierre Fabre Medicament","startDate":"2024-09-10","conditions":["Advanced Breast Cancer"],"enrollment":368,"completionDate":"2028-02"},{"nctId":"NCT07001618","phase":"PHASE2","title":"Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09","conditions":["NSCLC (Advanced Non-small Cell Lung Cancer)"],"enrollment":162,"completionDate":"2032-09"},{"nctId":"NCT06355024","phase":"PHASE2","title":"Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2024-05-11","conditions":["Triple-negative Breast Cancer"],"enrollment":10,"completionDate":"2025-01-01"},{"nctId":"NCT00354393","phase":"PHASE2","title":"Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2002-08","conditions":["Malignant Mesothelioma"],"enrollment":9,"completionDate":"2009-06"},{"nctId":"NCT00540982","phase":"PHASE1,PHASE2","title":"Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"1997-02-20","conditions":["Lung Cancer","Unspecified Adult Solid Tumor, Protocol Specific"],"enrollment":47,"completionDate":"2010-05-20"},{"nctId":"NCT03414658","phase":"PHASE2","title":"The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Adrienne G. Waks","startDate":"2018-06-21","conditions":["Breast Cancer"],"enrollment":100,"completionDate":"2026-05-31"},{"nctId":"NCT07041320","phase":"","title":"Oral Metronomic Vinorelbine and PD-1 Inhibitors in Elderly Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Anhui Chest Hospital","startDate":"2023-06-15","conditions":["Lung Cancer (NSCLC)","Elderly (People Aged 65 or More)"],"enrollment":40,"completionDate":"2026-12-31"},{"nctId":"NCT04299113","phase":"PHASE1","title":"Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2020-05-14","conditions":["Rhabdomyosarcoma"],"enrollment":38,"completionDate":"2027-05-22"},{"nctId":"NCT06343948","phase":"PHASE3","title":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-04-24","conditions":["HR+HER2- Breast Cancer"],"enrollment":383,"completionDate":"2026-05"},{"nctId":"NCT06383767","phase":"PHASE3","title":"A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2024-07-11","conditions":["Metastatic Breast Cancer"],"enrollment":378,"completionDate":"2028-07-31"},{"nctId":"NCT06311981","phase":"PHASE2","title":"Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients","status":"RECRUITING","sponsor":"Jian Chen","startDate":"2024-08-08","conditions":["Non-small Cell Lung Cancer","Older People","Carbon Ion Radiotherapy","Radiotherapy Side Effect"],"enrollment":29,"completionDate":"2026-06-17"},{"nctId":"NCT06533722","phase":"PHASE2","title":"Adaptive Therapy for Post-Second-Line Advanced Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2024-08-04","conditions":["HER2-negative Metastatic Breast Cancer"],"enrollment":10,"completionDate":"2025-05-28"},{"nctId":"NCT06678048","phase":"PHASE2","title":"Arsenous Acid for Refractory Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-10-23","conditions":["Breast Cancer"],"enrollment":12,"completionDate":"2026-10-23"},{"nctId":"NCT06244368","phase":"PHASE2","title":"GVM±R in Patients With Relapsed or Refractory Aggressive NHL.","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-01-17","conditions":["Peripheral T Cell Lymphoma","Diffuse Large B-cell Lymphoma"],"enrollment":115,"completionDate":"2027-12-30"},{"nctId":"NCT05299164","phase":"PHASE1","title":"GVM±R in Patients With Relapsed or Refractory Aggressive NHL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-05-15","conditions":["Non Hodgkin Lymphoma"],"enrollment":18,"completionDate":"2025-12-31"},{"nctId":"NCT06377566","phase":"PHASE2","title":"A Study of BV-AVD in People With Bulky Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-04-17","conditions":["Hodgkin Lymphoma"],"enrollment":71,"completionDate":"2027-04"},{"nctId":"NCT03242616","phase":"PHASE2","title":"PemVin vs Vin in Previously Treated Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2017-02-17","conditions":["Breast Neoplasms"],"enrollment":17,"completionDate":"2024-04-15"},{"nctId":"NCT04296162","phase":"PHASE2","title":"Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2020-03-10","conditions":["Breast Cancer"],"enrollment":178,"completionDate":"2027-06-30"},{"nctId":"NCT03257267","phase":"PHASE3","title":"Study of Cemiplimab in Adults With Cervical Cancer","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2017-09-05","conditions":["Squamous Cell Carcinoma (SCC)","Recurrent or Metastatic, Platinum-refractory Cervical Cancer"],"enrollment":608,"completionDate":"2023-04-20"},{"nctId":"NCT03442673","phase":"PHASE2","title":"Chemotherapy and G-CSF for Mobilization","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2018-09-17","conditions":["Multiple Myeloma"],"enrollment":137,"completionDate":"2024-05-01"},{"nctId":"NCT06775236","phase":"PHASE1,PHASE2","title":"Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2025-03-20","conditions":["Advanced Solid Tumors","Breast Cancer"],"enrollment":410,"completionDate":"2028-01-15"},{"nctId":"NCT02492711","phase":"PHASE3","title":"Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer","status":"COMPLETED","sponsor":"MacroGenics","startDate":"2015-08-24","conditions":["HER-2 Positive Breast Cancer","Metastatic Neoplasm"],"enrollment":624,"completionDate":"2022-06-14"},{"nctId":"NCT02489903","phase":"PHASE2","title":"RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)","status":"COMPLETED","sponsor":"EpicentRx, Inc.","startDate":"2015-06","conditions":["Small Cell Carcinoma","Carcinoma, Non-Small-Cell Lung","Neuroendocrine Tumors","Ovarian Epithelial Cancer"],"enrollment":139,"completionDate":"2021-12-06"},{"nctId":"NCT06875076","phase":"PHASE2","title":"Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma","status":"RECRUITING","sponsor":"The First Hospital of Jilin University","startDate":"2025-03-08","conditions":["Pretreated Pleural Mesothelioma"],"enrollment":25,"completionDate":"2029-12"},{"nctId":"NCT06857747","phase":"NA","title":"Disitamab Vedotin in Combination with Metronomic Chemotherapy in Advanced HER2-expressing Breast Cancer.","status":"NOT_YET_RECRUITING","sponsor":"QIAO LI","startDate":"2025-03-01","conditions":["Breast Cancer"],"enrollment":40,"completionDate":"2026-04-01"},{"nctId":"NCT00324805","phase":"PHASE3","title":"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-07-19","conditions":["Stage IB Lung Non-Small Cell Carcinoma AJCC v7","Stage IIA Lung Non-Small Cell Carcinoma AJCC v7","Stage IIB Lung Non-Small Cell Carcinoma AJCC v7","Stage IIIA Lung Non-Small Cell Cancer AJCC v7"],"enrollment":1501,"completionDate":"2025-01-31"},{"nctId":"NCT06839560","phase":"PHASE2","title":"Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined with VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients with Advanced HER2-Negative Breast Cancer with Brain Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-03-01","conditions":["Brain Metastasis from Advanced HER2-negative Breast Cancer"],"enrollment":102,"completionDate":"2028-09-10"},{"nctId":"NCT03443128","phase":"PHASE2","title":"Vinorelbine for Recurrent ALCL-2017","status":"COMPLETED","sponsor":"Children's Cancer Group, China","startDate":"2016-11","conditions":["Anaplastic Large Cell Lymphoma","Vinorelbine"],"enrollment":20,"completionDate":"2025-02"},{"nctId":"NCT06816771","phase":"PHASE2","title":"Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-02","conditions":["Rhabdomyosarcoma, Recurrent, Refractory"],"enrollment":38,"completionDate":"2026-12-31"},{"nctId":"NCT01214616","phase":"PHASE1","title":"BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-10-01","conditions":["Neoplasms"],"enrollment":17,"completionDate":"2013-05-01"},{"nctId":"NCT04701645","phase":"PHASE1","title":"Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-01","conditions":["Ovarian Cancer","Fallopian Tube Cancer","Peritoneal Cancer","Ovarian Cancer Stage III","Ovarian Cancer Stage IV","Fallopian Tube Cancer Stage IV","Fallopian Tube Cancer Stage III"],"enrollment":20,"completionDate":"2026-06-30"},{"nctId":"NCT03518606","phase":"PHASE1,PHASE2","title":"Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2018-06-20","conditions":["Advanced Solid Tumours","Breast Cancer","Head and Neck Cancer","Cervix Cancer","Prostate Cancer"],"enrollment":126,"completionDate":"2024-12-19"},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":["Metastatic Breast Cancer"],"enrollment":1460,"completionDate":"2025-12"},{"nctId":"NCT06771609","phase":"PHASE2","title":"Phase II Clinical Trial of PD-L1 in Combination with Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy with or Without Radiotherapy for Advanced Triple-negative Breast Cancer.","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-09-10","conditions":["Advanced Triple-negative Breast Cancer"],"enrollment":150,"completionDate":"2028-09-10"},{"nctId":"NCT06143553","phase":"PHASE3","title":"Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Yizhong Pharmaceutical Co., Ltd.","startDate":"2023-09-25","conditions":["Metastatic Breast Cancer (MBC)"],"enrollment":168,"completionDate":"2025-12"},{"nctId":"NCT02892123","phase":"PHASE1","title":"Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2016-09-30","conditions":["HER2-expressing Cancers"],"enrollment":279,"completionDate":"2024-10-31"},{"nctId":"NCT06102824","phase":"PHASE2","title":"Organoid-based Functional Precision Therapy for Advanced Breast Cancer","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2024-10-01","conditions":["HER2-negative Breast Cancer","Advanced Breast Cancer"],"enrollment":252,"completionDate":"2028-06-30"},{"nctId":"NCT06692491","phase":"PHASE2","title":"Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS","status":"NOT_YET_RECRUITING","sponsor":"Peking University Shenzhen Hospital","startDate":"2025-01-01","conditions":["Rare Tumour"],"enrollment":200,"completionDate":"2029-12-31"},{"nctId":"NCT00309998","phase":"PHASE2","title":"Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2005-09","conditions":["Lung Cancer"],"enrollment":50,"completionDate":""},{"nctId":"NCT03191786","phase":"PHASE3","title":"A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-09-11","conditions":["Non-Small Cell Lung Cancer"],"enrollment":453,"completionDate":"2023-10-25"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection","formulations":[{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Vinorelbine"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000021986","MMSL":"2135","NDDF":"004380","UNII":"Q6C979R91Y","VUID":"4023981","CHEBI":"CHEBI:480999","VANDF":"4020895","INN_ID":"6054","RXNORM":"114527","UMLSCUI":"C0078257","chemblId":"CHEMBL553025","ChEMBL_ID":"CHEMBL553025","KEGG_DRUG":"D01935","DRUGBANK_ID":"DB00361","PDB_CHEM_ID":" GDF","PUBCHEM_CID":"5311497","SNOMEDCT_US":"108792008","IUPHAR_LIGAND_ID":"7105","SECONDARY_CAS_RN":"125317-39-7","MESH_DESCRIPTOR_UI":"D000077235"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1994-","companyName":"Pierre Fabre","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"26.0 hours","clearance":"20.0 mL/min/kg","bioavailability":"27%","fractionUnbound":"0.87%","volumeOfDistribution":"23.0 L/kg"},"publicationCount":4139,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01CA04","allCodes":["L01CA04"]},"biosimilarFilings":[],"originalDeveloper":"Pierre Fabre","recentPublications":[{"date":"2025 Dec 24","pmid":"41888166","title":"Symptomatic and pathological features in chemical phlebitis rat model by injection vinorelbine via dorsal pedal vein.","journal":"Scientific reports"},{"date":"2026 Mar 19","pmid":"41877717","title":"Vinorelbine enhances the efficacy of oncolytic vaccinia virus in a preclinical model of ovarian high-grade serous carcinoma.","journal":"Molecular therapy. Oncology"},{"date":"2025","pmid":"41858972","title":"Locoregional recurrence of triple-negative breast cancer with low tumor-infiltrating lymphocytes: a case report.","journal":"The Pan African medical journal"},{"date":"2026 Mar 19","pmid":"41855500","title":"Real-World Evidence for Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin in Classical Hodgkin Lymphoma.","journal":"Blood advances"},{"date":"2026 Mar 18","pmid":"41851421","title":"Surface-engineered dual drug-loaded tumor-targeted liposomal nanoparticles to overcome the therapeutic resistance in glioblastoma multiforme.","journal":"Communications medicine"}],"companionDiagnostics":[],"genericManufacturers":10,"_genericFilersChecked":true,"genericManufacturerList":["Actavis Totowa","Dr Reddys","Ebewe Pharma","Fresenius Kabi Usa","Hikma","Hospira","Jiangsu Hansoh Pharm","Novast Labs","Rising","Teva Pharms Usa"],"status":"approved","companyName":"Pierre Fabre","companyId":"pierre-fabre","modality":"Small Molecule","firstApprovalDate":"1994","enrichmentLevel":4,"visitCount":3,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1994-12-23T00:00:00.000Z","mah":"PIERRE FABRE","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-07-27T00:00:00.000Z","mah":"ACTAVIS TOTOWA","brand_name_local":null,"application_number":"ANDA078011"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-07-27T00:00:00.000Z","mah":"JIANGSU HANSOH PHARM","brand_name_local":null,"application_number":"ANDA091106"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":26,"withResults":10},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:46:01.590238+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}